Analyst Price Targets — LMRI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 9:40 am | — | Barclays | $15.00 | $9.67 | TheFly | Lumexa Imaging price target lowered to $15 from $23 at Barclays |
| January 5, 2026 12:54 pm | — | Barclays | $23.00 | $17.55 | TheFly | Lumexa Imaging initiated with an Overweight at Barclays |
| January 5, 2026 12:08 pm | — | Deutsche Bank | $22.00 | $17.55 | TheFly | Lumexa Imaging initiated with a Buy at Deutsche Bank |
| January 5, 2026 11:37 am | — | Leerink Partners | $23.00 | $17.55 | TheFly | Lumexa Imaging initiated with an Outperform at Leerink |
| January 5, 2026 11:11 am | — | Raymond James | $23.00 | $17.55 | TheFly | Lumexa Imaging initiated with an Outperform at Raymond James |
| January 5, 2026 10:31 am | — | Wells Fargo | $22.00 | $17.55 | TheFly | Lumexa Imaging initiated with an Overweight at Wells Fargo |
| January 5, 2026 10:13 am | — | H.C. Wainwright | $22.00 | $17.55 | StreetInsider | Wells Fargo Starts Lumexa Imaging Holdings (LMRI) at Overweight |
| January 5, 2026 9:52 am | — | Jefferies | $23.00 | $17.55 | TheFly | Lumexa Imaging initiated with a Buy at Jefferies |
Latest News for LMRI
Lumexa Imaging Holdings, Inc. (LMRI) Q4 2025 Earnings Call Transcript
Lumexa Imaging remains a Buy, with Q4 2025 results clarifying the medium-term growth and margin trajectory. Advanced imaging volumes and mix are rising, driving superior unit economics and margin expansion; FastScan rollout is a key throughput catalyst. De novo center openings reached a record, with rapid breakeven timelines supporting compounding organic growth and future margin upside.
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI). The investigation focuses on Lumexa Imaging's executive officers and whether investor losses may be recovered under federal securities laws.
RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today announced certain financial results for the fourth quarter ended December 31, 2025, and reiterated full year 2026 guidance.
RALEIGH, N.C., Feb. 17, 2026 /PRNewswire/ -- Lumexa Imaging Holdings, Inc. ("Lumexa Imaging") (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, announced today that Caitlin Zulla, CEO, and Tony Martin, CFO, will participate in the following upcoming investor conferences: Raymond James Institutional Investors Conference, being held in Orlando, Florida, including a presentation at…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LMRI.
U.S. House Trading
No House trades found for LMRI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.